Commercialization of All-Natural Psychedelics Targeted Through Life Sciences Expertise VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce a service agreement with the IMPACT Clinical Trial…


Previous articleNuminus to expand state-of-the-art psychedelics research laboratory
Next articleThe Pitfalls and Challenges of Psychedelic Medicine